Positive Vasoreactivity Testing in Pulmonary Arterial Hypertension: Therapeutic Consequences, Treatment Patterns, and Outcomes in the Modern Management Era

• DOI: 10.1161/circulationaha.122.063821
• Publication Date: 2024-04-12T09:00:30Z
• Authors: Felix Gerhardt; Eva Fiessler; Karen M. Olsson; Moritz Z. Kayser; Gabor Kovacs; Henning Gall; H. Ardeschir Ghof...; Roza Badr Eslam; Irene M. Lang; Nicola Benjamin; Ekkehard Grünig; Michael Halank; Tobias J. Lange; Silvia Ulrich; Hanno Leuchte; Matthias Held; Hans Klose; Ralf Ewert; Heinrike Wilkens; Carmen Pizarro; Dirk Skowasch; Max Wissmüller; Martin Hellmich; Horst Olschewski; Marius M. Hoeper; Stephan Rosenkranz
• Keywords: Male; Adult; Cardiac Catheterization; Pulmonary Arterial Hypertension; 610 Medicine & health; Middle Aged; Pulmonary Artery; Calcium Channel Blockers; 2705 Cardiology and Cardiovascular Medicine; 03 medical and health sciences; 2737 Physiology (medical); Treatment Outcome; 0302 clinical medicine; Humans; Female; 10178 Clinic for Pneumology; Antihypertensive Agents; Retrospective Studies; Aged

Among patients with pulmonary arterial hypertension (PAH), acute vasoreactivity testing during right heart catheterization may identify vasoresponders, for whom treatment high-dose calcium channel blockers (CCBs) is recommended. However, long-term outcomes in the current era remain largely unknown. We sought to evaluate implications of response CCBs and other outcomes.